Anti-CD20 x Anti-CD28 Bispecific Antibody (IgG-IgG) (BSIG-H225)

Anti-CD20 x Anti-CD28 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD20 and anti-CD28 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Lymphoma therapy.

Datasheet

Specifications

Targets

CD20 & CD28

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD20

Host Animal 1

Human

Target 2

CD28

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma

Targets

Target 1

CD20

Gene ID

931

UniProt ID

A0A024R507

Alternative Names

MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1

Target 2

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Our services and products are only for lab research, not for any diagnostic or therapeutic use.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Germany
Heidenkampsweg 58, 20097 Hamburg, Germany
Email:

UK
167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Tel: 44-207-097-1828
Email: